Scholarlink

Aims <p>We investigated the efficacy of dapagliflozin, which is a sodium-glucose cotransporter 2 inhibitor, on uric acid (UA) in individuals with moderate-to-severe chronic kidney disease (CKD) (stage G3–4).</p> Methods <p>We retrospectively studied 46 patients (mean age: 66.6 ± 14.1&#xa0;years; 32 men and 14 women) after 12&#xa0;months of dapagliflozin treatment. We recorded the change in UA and urine protein. All of the patients had moderate-to-severe CKD (mean estimated glomerular filtration rate: 35.9 ± 10.9&#xa0;mL/min/1.73&#xa0;m<sup>2</sup>; stage G3, n = 32; G4, n = 14). The data of 46 matched patients with similar propensity scores (who did not take dapagliflozin) were analyzed as a control group.</p> Results <p>UA concentrations significantly decreased from baseline to 12&#xa0;months in the dapagliflozin group (6.4 ± 1.2&#xa0;mg/dL to 5.6 ± 1.4&#xa0;mg/dL, probability (p) &lt; 0.05) but UA concentrations did not change in the control group. In addition, UA concentrations were significantly lower in the dapagliflozin group than in the control group at 12&#xa0;months (5.6 ± 1.4&#xa0;mg/dL vs. 6.4 ± 1.4&#xa0;mg/dL, p &lt; 0.05). UA concentrations significantly decreased from baseline to 12&#xa0;months in patients with CKD stage G3 in the dapagliflozin group at 12&#xa0;months (6.4 ± 0.9&#xa0;mg/dL to 5.4 ± 1.0&#xa0;mg/dL, p &lt; 0.05) but UA concentrations did not change in patients with CKD stage G4.</p> Conclusions <p>Dapagliflozin can decrease UA concentrations in patients with moderate CKD. This finding suggests that dapagliflozin has a beneficial effect on UA metabolism in patients with moderate CKD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease

  • 期刊论文

  • 发表日期：

    2025年9月18日

查看全文
  • Katsunori Yanai,
  • Keiji Hirai,
  • Taisuke Kitano,
  • Haruhisa Miyazawa,
  • Kiyonori Ito,
  • Susumu Ookawara,
  • Yoshiyuki Morishita

摘要

Aims

We investigated the efficacy of dapagliflozin, which is a sodium-glucose cotransporter 2 inhibitor, on uric acid (UA) in individuals with moderate-to-severe chronic kidney disease (CKD) (stage G3–4).

Methods

We retrospectively studied 46 patients (mean age: 66.6 ± 14.1 years; 32 men and 14 women) after 12 months of dapagliflozin treatment. We recorded the change in UA and urine protein. All of the patients had moderate-to-severe CKD (mean estimated glomerular filtration rate: 35.9 ± 10.9 mL/min/1.73 m2; stage G3, n = 32; G4, n = 14). The data of 46 matched patients with similar propensity scores (who did not take dapagliflozin) were analyzed as a control group.

Results

UA concentrations significantly decreased from baseline to 12 months in the dapagliflozin group (6.4 ± 1.2 mg/dL to 5.6 ± 1.4 mg/dL, probability (p) < 0.05) but UA concentrations did not change in the control group. In addition, UA concentrations were significantly lower in the dapagliflozin group than in the control group at 12 months (5.6 ± 1.4 mg/dL vs. 6.4 ± 1.4 mg/dL, p < 0.05). UA concentrations significantly decreased from baseline to 12 months in patients with CKD stage G3 in the dapagliflozin group at 12 months (6.4 ± 0.9 mg/dL to 5.4 ± 1.0 mg/dL, p < 0.05) but UA concentrations did not change in patients with CKD stage G4.

Conclusions

Dapagliflozin can decrease UA concentrations in patients with moderate CKD. This finding suggests that dapagliflozin has a beneficial effect on UA metabolism in patients with moderate CKD.